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ABSTRACT 
To identify new host factors that 
modulate the replication of influenza A 
virus, we performed a yeast two-hybrid 
screen using the cytoplasmic tail of matrix 
protein 2 from the highly pathogenic H5N1 
strain. The screen revealed a high-score 
interaction with cyclin D3, a key regulator 
of cell cycle early G1 phase. M2–cyclin D3 
interaction was validated through GST 
pull-down and recapitulated in influenza 
A/WSN/33-infected cells. Knockdown of 
Ccnd3 by small interfering RNA 
significantly enhanced virus progeny titers 
in cell culture supernatants. Interestingly, 
the increase in virus production was due to 
cyclin D3 deficiency per se, and not merely 
a consequence of cell cycle deregulation. A 
combined knockdown of Ccnd3 and Rb1, 
which rescued cell cycle progression into 
the S phase, failed to normalize virus 
production. Infection by IAV triggered 
redistribution of cyclin D3 from the nucleus 
to the cytoplasm followed by its 
proteasomal degradation. When 
over-expressed in HEK 293T cells cyclin 
D3 impaired binding of M2 with M1, which 
is essential for proper assembly of progeny 
virions, lending further support to its role as 
a putative restriction factor. Our study 
describes the identification and 
characterization of cyclin D3 as a novel 
interactor of influenza A virus M2 protein. 
We hypothesize that competitive inhibition 
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of M1–M2 interaction by cyclin D3 impairs 
infectious virion formation and results in 
attenuated virus production. In addition, we 
provide mechanistic insights into the 
dynamic interplay of influenza virus with 
the host cell cycle machinery during 
infection. 
 
INTRODUCTION 
The threat of influenza infection is felt 
globally as the disease leads to an estimated 
3 to 5 million cases of severe illness, and 
about 250,000 to 500,000 deaths each year 
(1). Although the strategy of antagonizing 
influenza infection through vaccination has 
been partially successful, the necessity for 
effective antiviral agents is underscored by 
the toxic side effects of currently available 
drugs and the emergence of drug-resistant 
variants (2-4). Influenza viruses, like any 
other viruses, are obligate intracellular 
pathogens that exploit the host cellular 
machinery to replicate. The identification of 
cellular mechanisms required for virus life 
cycle not only sheds light on its trafficking 
characteristics but also provides strategies 
for interfering with host factors as an 
alternative approach to inhibit viral 
infection.  
Elucidating host-pathogen interactions as 
an unbiased approach to gain insights into 
disease pathogenesis has received ample 
attention. Various functional assay systems 
have been used for screening host factors 
involved in the influenza virus replication 
cycle thus far. From RNA interference 
(RNAi)-based genome-wide screening 
strategies in Drosophila (5) and mammalian 
systems (6-9) to other approaches including 
proteomics (10,11), yeast two-hybrid (Y2H) 
analyses (7,12), as well as microarrays 
(7,13-15), extensive information has been 
acquired. Multiple cellular networks have 
been implicated in influenza virus 
replication either through direct 
protein-protein interactions (10,16) or 
signaling pathways (17). Although these 
strategies unveiled hundreds of genes 
important for the virus life cycle, their 
functional relevance and molecular 
mechanisms are still poorly understood. 
Amongst others, effort has been invested to 
dissect how the cellular interactors of viral 
ribonucleoprotein (vRNP) complexes 
regulate the replication and transcription of 
influenza virus (18). Host interactors of the 
non-structural protein 1 (NS1), a 
multifunctional protein modulating several 
aspects of the virus replication cycle with a 
major role in inhibiting interferon mediated 
immune response, have also been 
extensively studied (16). However, little 
attention has been drawn to identify cellular 
factors associated with the viral matrix 
protein 2 (M2).  
We reasoned that the integral membrane 
proteins of the viral envelope would interact 
with cellular factors at various stages: 
endosomal fusion and release of the genetic 
material during entry, transport from 
endoplasmic reticulum (ER) to the plasma 
membrane and during assembly and 
budding of nascent virions. M2 is a minor 
protein of the viral envelope that forms a 
homotetramer in its native state (19,20). 
Interestingly, M2 possesses the longest 
C-terminal tail among the three viral 
envelope proteins, namely hemagglutinin 
(HA), neuraminidase (NA), and M2. It is an 
ion channel that was initially discovered as 
the target of the anti-viral drug amantadine 
and facilitates diffusion of protons to the 
interior of the endosomally entrapped virus 
(21). Low pH induces a conformational 
change in HA and subsequently triggers 
fusion with the endosomal membrane 
during virus entry (22). M2 is a 97-residue 
single-pass membrane protein that displays 
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considerable pleiotropism. It determines the 
filamentous morphology of some viral 
strains through binding to cholesterol 
(23-25). The cytoplasmic tail (CT) of M2 
interacts with M1 at the site of virus 
budding for efficient packaging of virus 
particles (26,27). Rossman et al reported a 
role of M2-CT in mediating 
cholesterol-dependent alteration in 
membrane curvature at the neck of budding 
virions, leading to host ESCRT 
pathway-independent membrane scission 
(28).  
Altogether, these studies provide 
evidence that influenza M2, especially the 
CT domain, plays a critical role in multiple 
steps of the virus life cycle. Hence, the 
identification of cellular interactors of M2 
would provide mechanistic insights into 
influenza pathogenesis and possibilities for 
development of novel strategies to interfere 
with multiple steps of the infection process. 
By using M2-CT as bait, we screened a 
human placenta cDNA library to identify 
host proteins that either facilitate or restrict 
viral infection. Cyclin D3, a key regulator of 
cell cycle G0/G1 phase progression, was 
uncovered as a novel host factor interacting 
with M2-CT. The physical interaction 
between M2 and cyclin D3 was confirmed 
in virus-infected cells. IAV infection 
resulted in host cell cycle arrest in the 
G0/G1 phase, which was accompanied by 
cyclin D3 relocalization and degradation. 
Using a combination of small interfering 
RNA (siRNA) mediated genetic analyses 
we further showed that cyclin D3 restricts 
IAV production, independent of its role in 
cell cycle. The restriction of cyclin D3 on 
IAV life cycle did not impair viral protein 
synthesis, but interfered with M1–M2 
binding, which may result in defective 
assembly and release of progeny virions. 
The role of cyclin D3 in the context of 
influenza infection has not been described 
previously. More interestingly, our results 
suggest a novel function of cyclin D3 that is 
beyond its classical function in cell cycle 
regulation. 
 
RESULT 
Identification of cyclin D3 as M2-CT 
binding protein 
The IAV M2 ion channel protein is a 
multifunctional protein with a highly 
conserved sequence among influenza A 
virus isolates that approaches 95% identity 
in some regions (29,30). Among the three 
viral envelope proteins, M2 possesses the 
longest CT with a high probability of 
interactions with the cellular machinery at 
various steps of the virus life cycle. These 
include fusion, intracellular trafficking 
through the secretory pathway (31), as well 
as virus assembly and budding at the plasma 
membrane (24,32). It is of considerable 
interest to identify intracellular interactors 
of M2-CT, not only to elucidate cellular 
components that are exploited by influenza 
but also to understand host defenses 
involved in restricting virus life cycle. To 
this end, a random-primed cDNA library 
from human placenta was screened by Y2H 
using the IAV M2-CT as bait (Figure 1A). 
The screening revealed human cyclin D3 
(GenBank accession no. NM_001760.2) as 
one of the most prominent interactors of 
M2-CT as summarized in Table 1. Sequence 
alignment of the positive clones pointed to 
amino acid residues 138 to 251 as the 
minimal interacting domain for M2-CT 
(Figure 1B). The M2-binding domain on 
cyclin D3 is largely outside of its cyclin box, 
which is responsible for binding to and 
activation of cyclin dependent kinases 
(33,34) and also the region in which the 
greatest homology occurs among the D-type 
cyclins (35). This finding, together with the 
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absence of other cyclins among positive 
clones, suggests a certain degree of 
specificity of the interaction, which was 
tested in the next series of experiments. 
Cyclin D forms a complex with and 
functions as a regulatory subunit of cyclin 
dependent kinase (CDK) 4 and 6, whose 
activity is required in the cell cycle early G1 
phase (36). There are three early G1 phase 
D-type cyclins (D1, D2 and D3), which are 
functionally related with tissue-specific 
expression profiles (37-43). Our results 
from Y2H screening indicate that only 
cyclin D3 but not the other two D-type 
cyclins interact with M2-CT. We first 
checked the specificity of this interaction in 
human A549 lung epithelial cells. 
GST–M2-CT fusion protein was purified 
and incubated with wild-type cell lysate to 
pull-down endogenous D-type cyclins. 
Cyclin D3 bound specifically to 
GST–M2-CT and not to either GST or 
beads (Figure 1C). Altogether, these results 
confirm that cyclin D3 binds to the IAV 
M2-CT. 
To examine the intracellular association 
of M2-CT with cyclin D3 during the IAV 
life cycle, co-immunoprecipitation 
experiments were performed from 
virus-infected cells. HEK 293T cells were 
transiently transfected with a plasmid 
encoding flag-tagged cyclin D3 (cyclin 
D3-Flag) and infected with influenza 
A/WSN/33 virus. Cell lysates were 
immunoprecipitated with anti-flag antibody 
and immunoblotted with anti-M2 antibody. 
As shown in Figure 1D (lane 1), M2 was 
found to co-purify with cyclin D3, 
demonstrating their physical interaction 
during virus infection, either directly or 
through a common interactor. No interaction 
was observed in control samples, where 
cells were either mock transfected and 
immunoprecipitated with anti-flag antibody 
(Figure 1D, lane 2) or transfected with 
cyclin D3-flag and immunoprecipitated with 
isotype control antibody (Figure 1D, lane 3). 
These data validate cyclin D3 as a bona fide 
interactor of influenza M2, corroborating 
our results from the Y2H screening.  
The specificity of interaction between 
cyclin D3 and M2 was tested using a panel 
of exogenously expressed cyclins (cyclin 
D1, D2, D3, and E1). Although, M2 appears 
to interact with other cyclins to some degree 
when they are over-expressed, we 
consistently found that it has the strongest 
interaction with cyclin D3 (Figure 1E). 
 
IAV infection induces cyclin D3 
relocalization and targets it for proteasomal 
degradation 
To understand the functional relevance of 
cyclin D3-M2 interaction in virus infected 
cells, we tested their subcellular distribution 
through immunofluorescence imaging. To 
achieve unbiased analysis, A549 cells were 
infected with influenza A/WSN/33 virus at 
an MOI of 0.5 to have a mixed population 
of infected and uninfected cells in the same 
sample. Cells were fixed at 24 h 
post-infection (p.i.) and stained for cyclin 
D3 and M2 proteins. In uninfected cells, 
cyclin D3 resides both in the nucleus and 
cytoplasm with only the nuclear 
CDK4/6-cyclin D3 complex displaying 
retinoblastoma (Rb)-directed kinase activity 
(44). Interestingly, upon virus infection, a 
much weaker cyclin D3 signal was observed 
in the nuclei of infected cells compared to 
control cells, as revealed by M2 staining. 
These results suggest that cyclin D3 is 
redistributed from the nucleus to the cytosol 
as a response to infection (Figure 2A, upper 
panels). The effect of M2 protein on cyclin 
D3 relocalization was recapitulated in 
analogous experiments using A549 cells 
expressing M2 protein alone (Figure 2A, 
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lower panels), which resulted in the 
apparent reduction of cyclin D3 from the 
nucleus, similar to the phenotype induced 
by viral infection. 
To address the reduction of cyclin D3 
from the nucleus upon virus infection, we 
fractionated both control and infected cells 
into cytosol and nuclear material to measure 
cyclin D3 levels. Cytoplasm- and 
nuclear-enriched extracts were prepared 
from A/WSN/33-infected (MOI of 2 to 
achieve a more homogeneous infection of 
the cell culture) and uninfected A549 cells. 
Lamin B1 and GAPDH were used as 
markers to verify clear separation of nuclear 
and cytoplasmic fractions. Total 
intracellular level of cyclin D3 in 
virus-infected cells decreased to ~60% of 
that observed in mock-infected cells (Figure 
2B; Figure 2C, upper panel). Densitometric 
analysis indicates that 10% of total cyclin 
D3 was found in the nucleus of uninfected 
cells. This is very likely an underestimation 
since cyclin D3, being soluble, would leak 
from the nuclear into the cytoplasmic 
fraction during the experimental procedures. 
The percentage of nuclear-cyclin D3 
dropped to less than 4% at 8 h p.i. (Figure 
2C, lower panel), indicating translocation of 
cyclin D3 from nucleus to cytoplasm in 
virus-infected cells. This significant (>60%) 
reduction of nuclear-cyclin D3 detected 
through biochemical measurement 
confirmed our immunofluorescence data on 
its subcellular relocalization.  
We further verified colocalization of 
cyclin D3 with that of M2 through infection 
of A/WSN/33 in cyclin D3-expressing cells. 
Since at 24 h p.i. most of cyclin D3 is 
degraded, we selected an earlier time point 
and treated mock and virus-infected cells 
with MG-132 to increase the signal strength 
of cyclin D3. Indeed, at 15 h post infection, 
we could capture colocalization of influenza 
M2 and cyclin D3 along the secretory 
pathway (Figure 2D). Most of cyclin D3 
appeared in the cytosolic fraction under 
these conditions. Interaction of cyclin D3 
with M2， combined with its enrichment in 
the cytosol upon M2 expression strongly 
favors that this association must occur in the 
cytosol, either directly or as a complex 
presumably en route to assembly and 
release of intact progeny virions. 
The induction of D-type cyclins is growth 
factor dependent, and both mRNAs and 
proteins exhibit moderate oscillations in 
continuously proliferating cell populations 
(37,38,45-48). Given the decrease in total 
intracellular cyclin D3 levels observed in 
virus-infected cells, we next addressed 
whether influenza virus modulates cyclin 
D3 protein levels in addition to altering its 
subcellular localization. The expression 
profiles of cyclin D3 and another cell cycle 
G1 phase regulator, cyclin E, were 
measured through immunoblotting. Cyclin 
D3 was dramatically downregulated by IAV 
infection to almost undetectable levels 
compared to uninfected cells at 24 h p.i. 
(Figure 3A, upper panel). A time-course 
analysis revealed that the steady-state levels 
of cyclin D3 started declining at 6 h p.i., and 
decreased by approximately 50% at 9 h p.i. 
(Figure 3A, lower panel). Cyclin E, which is 
activated at the late stage of cell cycle G1 
phase to facilitate G1/S transition, displayed 
only a moderate reduction under identical 
conditions (Figure 3A), contrary to the 
finding by He et al where cyclin E was 
vastly downregulated by IAV infection (49). 
However, no quantitative analysis was 
provided in their study, preventing us from 
comparing the reduction level. It is worth 
noting that cyclin E exists as multiple 
proteins ranging in size from 
Mr35,000-50,000 in tumor cell lines as 
illustrated by others (see also Figure 3, 
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panel A) (50,51). However, only one band 
size of cyclin E was shown in their study, 
although the same cell type was used. The 
differential regulation of cyclin D3 and 
cyclin E indicates that IAV infection 
specifically deregulates components in the 
early G1 phase (G0/G1 phase) of the cell 
cycle machinery.  
To further investigate the mechanism of 
virus induced cyclin D3 downregulation, we 
determined the involvement of the 
proteasomal degradation pathway in this 
process. Cells were infected with 
A/WSN/33 virus in the absence or presence 
of proteasome inhibitors, MG-101 or 
MG-132, and tested for cyclin D3 levels. 
MG-101, also known as calpain inhibitor I, 
inhibits both proteasome and calpain 
activities (52). Calpain is a 
calcium-dependent protease that produces 
limited proteolysis of its substrates. 
Resulting fragments are further degraded by 
other proteolytic pathways including 
proteasome (52). Calpain has been reported 
to regulate cyclin D1 at the 
posttranscriptional level (53). MG-132 is a 
proteasome inhibitor that prevents 
degradation of ubiquitin-conjugated proteins 
(54). Uninfected cells were treated with the 
same drugs to control for the baseline 
oscillation of cyclin D3 levels. Proteasome 
inhibition did not affect cyclin D3 
abundance in uninfected cells; however, 
blocking proteasome activity led to a 
significant stabilization of cyclin D3 in 
virus-infected cells. MG-101 and MG-132 
treatments blocked cyclin D3 degradation 
by ~50% and ~60% respectively, compared 
to vehicle control (DMSO) treated group, as 
measured by densitometric analysis of 
immunoblots (Figure 3B). Thus, an obvious 
rescue of cyclin D3 was observed after one 
round of infection (9 h p.i.) through the use 
of proteasome inhibitors. The regulation of 
other cell cycle moderators and were also 
investigated. Although viral infection also 
resulted in cyclin D1, cyclin dependent 
kinase 4 (CDK4), and CDK6 
downregulation on protein level (Figure 4A). 
The level of down regulation is not as robust 
as that of cyclin D3, and their protein levels 
could not be rescued by protease and 
calpain inbihitor when compared to cyclin 
D3 (Figure 4B). These suggest that IAV 
posts a cyclin D3 specific effect during 
infection. 
Our data indicate that IAV infection 
results in reduced cyclin D3 levels in the 
nucleus of virus-infected cells. This 
phenotype is triggered by translocation of 
nuclear-cyclin D3 into the cytoplasm, where 
IAV facilitates proteasomal degradation of 
cytoplasmic-cyclin D3.  
 
Influenza A/WSN/33 virus infection arrests 
cell cycle in G1 phase 
The principal role of the D-type cyclins is 
to act as growth factor sensors, converting 
environmental signals into fuel for the cell 
cycle engine. The interaction between cyclin 
D3 and M2-CT during viral life cycle 
implies a potential regulation of host cell 
cycle by IAV. This is supported by our 
observation that cyclin D3 is actively 
removed from the nucleus and degraded by 
the proteasome in virus-infected cells. To 
address whether the cell cycle is 
compromised, a quantitative profiling of cell 
cycle kinetics was performed on 
virus-infected A549 cells. Using an 
asynchronously growing cell population, we 
found that virus infected cells accumulated 
at the G1 phase when compared to 
uninfected group (data not shown). To 
reduce variability owing to a mixed 
population of cells in differential phases of 
the cell cycle, we first synchronized them 
prior to infection in G1 using lovastatin, a 
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fungal metabolite shown to affect cell cycle 
distribution in a reversible manner (55). 
Cells were released from the lovastatin 
block and stimulated with mevalonate at the 
time of infection to trigger progression into 
later cell cycle stages. BrdU incorporation 
and DNA content staining showed that virus 
infection brought about a cell cycle arrest at 
9 h p.i. (Figure 5A). The overlay of cell 
cycle patterns of virus-infected and 
uninfected cells indicates that infection 
decreased the peaks representing cells in the 
S and G2/M phases (Figure 5B). The 
percentages of cells in G1 phase exhibited a 
progressive, time-dependent drop from 83.0 
± 2.1% to 80.1 ± 0.9%, and subsequently 
45.7 ± 2.8% (at 0, 9, and 24 h p.i. 
respectively; means ± SD of three 
experiments) in the mock-infected samples. 
This reduction reflects progression of cells 
through the G1 phase, followed by entry 
into the later stages of the cell cycle. In 
contrast, cells infected by A/WSN/33 virus 
remained in G1 with percentage of cells in 
G1 phase hovering above 80% at all time 
points (Figure 5C). Our results demonstrate 
that IAV infection impairs progression of 
cell cycle through the G1/S intersection. 
To further prove that IAV infection 
induced cell cycle arrest in the G1 phase, we 
took a separate approach. Cells were 
pre-accumulated in the G2/M phase by 
treating with RO-3306, a CDK1 inhibitor 
(56). At 0 h p.i., both A/WSN/33-infected 
and control samples had comparable 
percentages of cells in all phases of the cell 
cycle (Figure 5D). Similar to the result 
obtained with lovastatin, cell cycle pattern 
of virus-infected cells showed lower peaks 
for both S and G2/M phases when compared 
to uninfected cells (Figure 5E). Upon 
recovery of cells from drug restriction, both 
uninfected and infected cells resumed 
division and initiated a new round of cell 
cycle, displaying increased percentage of 
cells representing G0/G1 phase at 9 h p.i.; 
only uninfected cells, however, progressed 
further into the S phase. The percentage of 
cells in G0/G1 phase dropped from around 
85% to 65% in control sample, whereas it 
remained constant in IAV-infected cells 
(Figure 5F). Collectively, these results 
indicate that IAV infection perturbs normal 
cell cycle progression in human cell lines 
and installs a block at the G0/G1 phase. 
D-type cyclins activate CDK4/6, which 
initiate phosphorylation of Rb at multiple 
sites. Hyperphosphorylated Rb (ppRb) 
releases transcription factor E2F, and leads 
to the activation and transcription of cell 
cycle progression responsive genes 
(38,57,58). To test whether IAV induced 
cell cycle arrest was imposed by Rb, the 
phosphorylation status of Rb was monitored. 
Phosphorylation on serine-780 (ppRb S780) 
is specifically catalyzed by cyclin 
D-CDK4/6 complex, but not cyclin 
E-CDK2 (59). Not surprisingly, IAV 
infection progressively resulted in 
diminished levels of ppRb S780 as a 
function of time (Figure 6A). Furthermore, 
serine-807/811 phosphorylation on Rb 
(ppRb S807/811), which affects the S phase 
of cell cycle displayed a similar trend (60) 
(Figure 6A), an observation consistent with 
the virus-induced block at the G0/G1 phase. 
In line with the downregulation of ppRb 
proteins, accumulation of 
hypo-phosphorylated Rb (pRb) was 
observed (Figure 6A).  
Inhibition of cell cycle can also occur 
through induction of cyclin-dependent 
kinase inhibitors (CKIs). P21WAF1/CIP1 is a 
‘universal’ CKI that inhibits both cyclin and 
CDK subunits to install a p53-dependent G1 
phase arrest (61). Interestingly, upon 
infection p21WAF1/CIP1 was downregulated 
through proteasomal degradation, indicating 
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that IAV induced G0/G1 arrest was not 
mediated through the p53/p21WAF1/CIP1 
pathway (Figure 6A and 6B). Expression 
levels of p16 from the INK4 family of CKI, 
which specifically inhibits the catalytic 
subunits of CDK4 and CDK6, were also 
measured. No increase in p16INK4A was 
observed even after prolonged infection 
time (data not shown). 
From the results described above, we 
conclude that IAV infection downregulates 
cyclin D3 levels, which in turn inhibits 
CDK4/6 activation and ultimately results in 
reduced Rb phosphorylation. Consequently, 
pRb sequesters the transcription factor E2F, 
which prevents cell cycle entry into the S 
phase (58). 
 
Cyclin D3 negatively modulates influenza 
virus infection 
To establish a functional relevance for 
cyclin D3 in IAV pathogenesis, we studied 
the effect of Ccnd3 knockdown on virus 
replication. To avoid off-target effects 
imposed by the use of siRNA pools, we 
used an individual siRNA duplex from 
published literature (CCND3 #1) for 
generating a knockdown (62). SiRNA 
CCND3 #1 effectively reduced endogenous 
cyclin D3 expression levels by over 90% at 
72 h post transfection, compared to a 
nonspecific control siRNA (NT) (Figure 
7A). Control (NT siRNA-treated) and cyclin 
D3-deficient cells were infected with 
A/WSN/33 at an MOI of 0.01 to allow 
multiple rounds of infection. Viral titers 
obtained from cyclin D3-deficient cells 
were at least 10-fold greater than that from 
control cells (Figure 7B, left panel). Since 
cyclin D3–M2 interaction was identified 
using avian M2-CT, we measured the effect 
of Ccnd3 knockdown on the replication of 
highly pathogenic H5N1 avian influenza 
virus and observed a more than 10-fold 
higher progeny virus production in cyclin 
D3-deficient cells when compared to control 
group at 24 h p.i. (Figure 7B, right panel). 
The difference in production of H5N1 virus 
was less significant at 48 h p.i. (~2.5-fold), 
most likely due to the cytopathic effect of 
H5N1 virus in a limited cell culture system. 
To differentiate whether the increased 
progeny virus titer was intrinsic to the 
absence of cyclin D3 protein or a 
consequence of cell cycle arrest induced by 
cyclin D3 silencing, we next used 
combinations of siRNAs targeting various 
steps in the cell cycle to modulate its 
progression. Concomitant knockdown of 
Ccnd3 and Rb1 rescued cells from the 
G0/G1 phase block imposed by cyclin 
D3-deficiency, allowing us to measure the 
effect of cyclin D3 alone on virus 
replication. In addition, we included a 
Ccne1 knockdown, which induced cell cycle 
arrest at the G1/S interface without affecting 
cyclin D3 levels. To gain further confidence 
in the specificity of the cyclin D3 siRNA, 
we included a second siRNA duplex 
specific for cyclin D3 (CCND3 #2). Both 
individual siRNAs and 
siRNA-combinations resulted in significant 
reduction of the desired gene expressions 
(Figure 7C). In control siRNA treated cell 
population, around 55% percent cells were 
found in G0/G1 phase of the cell cycle. As 
expected, knockdown of Ccnd3 alone 
arrested cell cycle progression in A549 cells 
with ~65% (CCND3 #1) or ~70% (CCDN3 
#2) cells in G0/G1 phase when compared to 
cells treated with NT siRNA. A concomitant 
Ccnd3/Rb1 knockdown rescued cell cycle 
progression into the S phase. Knockdown of 
Ccne1 expression in A549 cells induced a 
more robust cell cycle G0/G1 phase 
accumulation than Ccnd3 knockdown with 
~80% cells in G0/G1 phase (Figure 7D). For 
all siRNA-mediated knockdowns, cells were 
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subjected to infection with A/WSN/33 virus 
at an MOI of 0.01 at 72 h post transfection 
for progeny virus production. Ccnd3 
knockdown with the two individual siRNA 
duplexes increased progeny virus titers by 
approximately one log. Despite the rescue in 
cell cycle progression, a double knockdown 
of Ccnd3/Rb1 did not normalize virus 
production when compared to NT siRNA 
treated cells. A 5-fold difference in viral 
titers persisted between control cells 
compared to those that harbored a double 
knockdown in Ccnd3/Rb1. Virus titers from 
cells with Ccne1 knockdown were 
comparable to that from Ccnd3/Rb1 double 
knockdown (Figure 7E, left panel).  
To study whether the inhibitory role of 
cyclin D3 on viral replication is also 
applicable to the other IAV strains, two 
clinical isolates were tested. At both 24 and 
48 h p.i., equivalent or higher virus titers for 
influenza A/HK/1/68 (H3N2) and 
A/HK/54/98 (H1N1) viruses confirmed our 
results with A/WSN/33 (Figure 7E, middle 
and right panels). 
To examine the distribution of D-type 
cyclins in the context of natural infection, 
we determined their expression in the 
human airway, in particular, human 
bronchial epithelial cells (HBEC) and 
pneumocytes. Although cyclin D3 mRNA 
was expressed at lower levels compared to 
the other two D-type in both cell types 
(Figure 8A), comparable protein amounts of 
cyclin D3 were detected in A549, HBEC, 
and pneumocytes (Figure 8B). Cyclin D2 
expression could be detected in the two 
primary cells but not in A549 (Figure 8B). 
Collectively, cyclin D3 is expressed in 
tissues along the natural infection route of 
IAV. To validate its functional relevance in 
these cells, we performed a knock-down of 
cyclin D3 in HBECs to study its effect on 
influenza virus production. As observed 
with A549 cells, cyclin D3-deficiency in 
HBEC resulted in ~10-fold increase in viral 
titers, supporting our conclusions from 
experiments performed in actively dividing 
cells (Figure 8C, 8D). 
 
 
Cyclin D3 inhibits M2 and M1 interaction, 
but not viral protein synthesis 
To understand the mode of cyclin 
D3-imposed restriction of IAV production, 
we first measured whether viral protein 
synthesis was affected by cyclin D3. To 
separate the effect of cyclin D3-deficiency 
from cell cycle arrest, we used the 
Ccnd3/Rb1 double knockdown. Multiple 
time points were selected to measure viral 
protein synthesis within a single cycle of 
infection. Knockdown cells did not display 
enhanced viral protein synthesis compared 
to control cells (Figure 9), suggesting that 
the effect of cyclin D3 on IAV infection 
probably occurred at a later step post viral 
protein translation.  
The biogenesis of viral particles involves 
proper packaging and assembly of viral 
proteins and RNA to form intact virions at 
discrete budding sites. M2 is a 
multifunctional protein: its cytosolic tail 
interacts with M1, promoting the 
recruitment of viral internal proteins and 
vRNA to the plasma membrane for efficient 
virus assembly (27). We postulated that 
binding of cyclin D3 to M2-CT might affect 
M1–M2 interaction, resulting in attenuated 
virus release due to either i) production of 
defective virus particles due to improper 
packaging or ii) incomplete assembly of 
virions and hence generation of fewer 
particles. To test this hypothesis, HEK 293T 
cells were co-transfected with cyclin D3, 
M1, and M2. Cells expressing M1 and M2 
without exogenous cyclin D3 were used as 
control. For both conditions, M1–M2 
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binding was detected through 
co-immunoprecipitation followed by 
immunoblotting (Figure 10A, left panel, 
lane 1). Upon over-expression of cyclin D3, 
the level of M1 that co-precipitated with M2 
was significantly lower than the amount 
obtained in the absence of cyclin D3 (Figure 
10A, left panel, lane 2). Densitometric 
analysis revealed that a reduction of 
approximately 70% in binding of M1 to M2 
was observed when cyclin D3 was 
over-expressed (Figure 10A, right panel). 
An isotype control antibody used in parallel 
did not bind to M1 (Figure 10A, left panel, 
lane 3). Our results demonstrate that: i) 
cyclin D3 does not affect viral protein 
synthesis during IAV life cycle and ii) 
interaction between M1 and M2 is 
significantly attenuated in the presence of 
cyclin D3. We propose that through 
competition with M1 for M2 binding, cyclin 
D3 restricts IAV production either through 
reduced or defective progeny virion 
formation. 
To test this hypothesis, cyclin 
D3-deficient cells and control cells were 
infected with A/WSN/33 to measure plasma 
membrane expression of viral M2 protein 
within one cycle of infection. As illustrated 
in figure 6C, more M2 was detected at the 
plasma membrane in cyclin D3-deficient 
cells. This suggests that without the 
blockage imposed by cyclin D3, greater 
amount of M2 could reach the cell surface 
and/or at a faster pace, thus facilitating the 
recruitment of viral internal components to 
the plasma membrane for assembly and 
budding. This trend could be observed at 
both time intervals as summarized in figure 
10B. In addition, we could validate these 
results using confocal imaging. 
Overexpression of cyclin D3 resulted in 
both M1 and M2 being predominantly 
confined to the early secretory network 
compared to control cells with endogenous 
cyclin D3 levels, where a significant 
fraction of M2 appeared at the plasma 
membrane (Figure 10C). Interestingly, 
although absence of cyclin E1 (a weak 
interactor of M2), facilitates IAV progeny 
virus production, this effect occurs through 
a different mechanism as M2 surface 
expression remained unaffected in cells 
depleted of cyclin E1 (data not shown). 
 
DISCUSSION 
The search for the interactome of M2 
protein of IAV in host cells has been limited 
so far. Host proteins that M2 has been 
shown to exploit include Na+/K+-ATPase, 
heat shock protein 40 (Hsp40), and p58IPK 
(IPK, inhibitor of protein kinase) (63-67). In 
addition, the amphipathic helix located 
within the M2-CT binds to cholesterol and 
alters the local membrane curvature at the 
budding zone while providing a scaffold for 
M1 polymerization and filament elongation 
(68). Withdrawal of cholesterol or 
disruption of the M2 amphipathic helix 
inhibits viral filament formation (25). We 
previously identified annexin A6 as a novel 
interactor with the M2-CT, which impairs 
budding and release of IAV at late stages of 
the virus life cycle (69). More recently, M2 
was found to interact with the ATG8/LC3 
family of ubiquitin-related proteins residing 
on the autophagosomal membranes (70,71). 
A highly conserved LC3-interacting region 
(LIR) in M2 promoted binding and 
relocalization of LC3 to the plasma 
membrane. This mechanism allowed 
subversion of autophagy and facilitated 
inter-organism viral transmission by 
enhancing the stability of progeny virions.  
In the present study, we identified cyclin 
D3 as a novel interactor of IAV-M2 and 
systematically studied its role in the context 
of IAV infection. Being a key regulator of 
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cell cycle progression, Ccnd3 knockdown 
by default leads to cell cycle G0/G1 phase 
arrest, providing a favorable environment 
for IAV replication. Our results indiciate 
that cyclin D3 functions beyond its role in 
cell cycle in the context of influenza 
infection. The absence of cyclin D3 in 
combination with accumulation of cell cycle 
in G1 phase appear to have an additive 
effect on IAV progeny virus production 
indicating that cyclin D3-deficiency 
specifically facilitates influenza virus 
production independently of the cell cycle. 
Instead, co-immunoprecipitation with M2 
suggests that cyclin D3 impairs nascent 
virus production at a late stage of the virus 
life cycle by interfering with M1-M2 
binding (Figure 11). Our results illustrate 
yet another mechanism that IAV has 
evolved to counteract host defenses: cyclin 
D3 is redistributed from the nucleus to the 
cytoplasm, where it is targeted for 
proteasomal degradation. Indeed, 
mislocalization and subsequent 
downregulation of restriction factors is one 
of the recurring mechanisms viruses have 
adopted to overcome host defenses (72). 
The presence of M2 traps cyclin D3 in the 
cytoplasm through two possible 
mechanisms: i) M2 interacts with newly 
synthesized cyclin D3 and prevents it from 
translocating into the nucleus, or ii) cyclin 
D3 is retained by M2 in the cytoplasm after 
its nuclear export. A detailed mechanism of 
how cyclin D3 is targeted to the proteasome 
complex and which E3-ligase ubiquitylates 
it will be pursued in future investigations. 
Downregulation of cyclin D3 transcript was 
previously observed in H5N1 infected cells 
but its implication had not been addressed 
(73). Our study has expanded the repertoire 
of IAV-M2 host interactors, and proposes a 
novel function of cyclin D3 in the life cycle 
of IAV. 
Manipulation of the cell cycle machinery 
has been adopted by many viruses as a 
common strategy. For instance, HIV-1 
accessory protein Vpr is reported to induce 
arrest in G2 by activating protein 
phosphatase 2A (PP2A), which acts on 
mitosis inhibitors Wee1 kinase and Cdc25 
phosphatase (74). Similar to our findings, 
some other viral proteins have been found to 
bind members of the cyclin family. 
Persistent infection with borna disease virus 
(BDV) results in reduced G2 to M 
progression(75). Likewise, the 
nucleoprotein of SARS-CoV inhibits the 
activity of CDK4 by binding to cyclin D, 
which blocks S phase progression (76). 
Viral proteins associate with particular cell 
cycle components, thereby deregulating the 
host cell cycle clock to alter the 
environment for more efficient replication. 
It remains to be determined whether 
M2-cyclin D3 interaction inhibits the kinase 
activity of CDK4/6 after IAV infection. A 
cell cycle arrest in G0/G1 by IAV infection 
was first reported by He et al, although this 
phenomenon was not investigated in 
mechanistic terms (49). The non-structural 
protein 1 (NS1) of IAV was later discovered 
to interact with and inhibit the activity of the 
Ras homolog gene family member A 
(RhoA), providing some molecular insights 
into the mechanism of IAV-induced cell 
cycle perturbation (77). The present study 
quantitatively demonstrated that IAV 
infection imposes a specific G0/G1 arrest, 
and established cyclin D3 mislocalization 
and degradation following its interaction 
with M2 as the underlying molecular 
correlate. 
Co-evolution and adaptation of 
virus-host interactions is best described as a 
zero-sum biological arms race. However, 
owing to high mutation rates, viruses such 
as influenza are well equipped to rapidly 
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evolve strategies to evade host restriction 
factors. Consequently, in case of IAV 
infection, the effect of cyclin D3 is 
successfully antagonized by M2, which 
redirects cyclin D3 from the nucleus to the 
cytosol followed by proteasomal 
degradation, thereby granting an advantage 
to virus production. 
Our study provides important insights 
into the mechanism through which cyclin 
D3 restricts IAV infection. We 
demonstrated that the increase in progeny 
virus production upon Ccnd3 knockdown 
was not a result of enhanced viral protein 
synthesis in host cells. Instead, the 
inhibitory effect of cyclin D3 on IAV 
infection is due to its interaction with viral 
M2 protein, as measured by competitive 
co-immunoprecipitation assays. We 
hypothesize that cyclin D3-M2 interaction 
either masks the domain on M2 mediating 
binding to M1, or has a higher affinity than 
that between M1-M2. Another possibility is 
that cyclin D3-M2 interaction sequesters the 
amount of available M2. Consequently, 
limited-M1–M2 binding during the budding 
process of IAV infection results in less 
progeny virions being efficiently packaged 
and released from host cells. Several host 
factors have been identified that interfere 
with the late stage of viral life cycle, among 
which tetherin (also known as BST-2) is the 
best characterized. In addition, 
interferon-stimulated gene (ISG) products 
are a group of newly emerging host 
restriction factors that can control viral, 
bacterial, and parasite infection as 
exemplified by viperin and ISG15 to name a 
few (78-81). The current study includes 
cyclin D3 in the family of IAV budding 
inhibitors, and provides insights into the 
dynamic interplay between cyclin D3 and 
M2 during IAV infection. 
 
EXPERIMENTAL PROCEDURE 
Yeast two-hybrid screening 
Influenza A virus M2-CT 
(A/Goose/Guangdong/1/96; GeneBank 
access no. 81975894) was used as bait to 
screen for interactors from a random-primed 
human placenta cDNA library, which 
contains 10 million independent fragments. 
The cloning of bait and Y2H screening were 
performed by Hybrigenics (Paris, France). 
Briefly, M2-CT was fused with the LexA 
binding domain by subcloning it into the 
pB27 vector. The L40ΔGAL4 yeast strain 
was then transformed with pM2-CT bait 
plasmid and mated with Y187 yeast strain 
transformed by the prey library (82). Clone 
selection was performed on leucine, 
tryptophan, and histidine drop-out medium, 
and 273 positive diploids were picked. 
Identified prey fragments were then 
subjected to PCR and sequencing. After 
going through filtration and being divided 
into contigs, sequences were compared to 
the most updated Genbank database by 
using BLASTN to decode interactions. All 
interactions were assigned with computative 
confidence scores to assess interaction 
reliability (83). 
 
Cells and viruses 
Human alveolar basal epithelial (A549), 
human embryonic kidney (HEK 293T), and 
Madin-Darby canine kidney (MDCK) cells 
were purchased from ATCC. Human 
bronchial epithelial cells (HBEC) and 
primary pneumocytes were kindly donated 
by Dr. Michael Chi Wai Chan from School 
of Public Health, the University of Hong 
Kong. Dulbecco’s modified Eagle’s 
medium (DMEM) (Invitrogen) 
supplemented with 10% fetal bovine serum 
(FBS), 100U/ml penicillin and 100µg/ml 
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streptomycin (Invitrogen) was used to 
culture and maintain all cell types used. 
Influenza A virus strains A/WSN/33 
(H1N1), A/HK/1/68 (H3N2), A/HK/54/98 
(H1N1), and A/Vietnam/1203/2003 (H5N1) 
were propagated in MDCK cells 
supplemented with 0.3% bovine serum 
albumin (BSA) (Sigma-Aldrich) in the 
presence of 1 µg/ml tosylsulfonyl 
phenylalanyl chloromethyl ketone 
(TPCK)-treated trypsin (Thermo Scientific), 
and stored as virus stocks at -80ºC until 
further use. Viral titers were obtained by 
plaque assay on MDCK cells. Briefly, serial 
10-fold dilutions of virus stocks were 
adsorbed onto a confluent monolayer of 
MDCK cells for 1 h at 37 ºC. Next, viral 
inoculums were removed and cells were 
washed twice with phosphate-buffered 
saline (PBS), pH 7.4. Cells were then 
covered with 1% semisolid agar in DMEM 
complemented with 0.3% BSA and 1 µg/ml 
TPCK-treated trypsin. Three days after 
incubating the plates in an upside down 
manner, plaques were visualized by staining 
with crystal violet (84). 
 
Plasmids and antibodies 
Plasmid pCMV6-Flag-CCND3 was 
generated by subcloning the CCND3 open 
reading frame (ORF) (Homo sapiens, 
GenBank accession NM_001760.4) from 
plasmid pCMV6-CCND3-GFP (Origene 
Technologies) into the pCMV6-Entry vector 
at the Mlul and Sgfl restriction sites. 
Plasmid pCAGGS-M2-Flag, 
pCAGGS-M1-HA and rabbit anti-M1 pAb 
were kindly donated by Prof Adolfo 
García-Sastre (Icahn School of Medicine at 
Mount Sinai). 
The following primary antibodies were 
used in this study: mouse anti-cyclin D3 
monoclonal antibody (mAb) (clone DCS22) 
was purchased from Cell Signaling 
Technology; mouse anti-cyclin E mAb 
(clone HE12), mouse anti-influenza A M2 
mAb (clone 14C2), mouse anti-influenza A 
M1 mAb (clone GA2B), rabbit anti-p21 
polyclonal antibody (pAb) were purchased 
from Santa Cruz Biotechnology; mouse 
anti-influenza A M2 mAb (clone 14C2) was 
purchased from Thermo Scientific; mouse 
anti-flag mAb (clone M2) and mouse 
anti-c-myc mAb (clone 9E10) were 
purchased from Sigma-Aldrich; mouse 
anti-human hypophosphorylated 
retinoblastoma (pRb) mAb (clone G99-549), 
mouse anti-Rb (ppRb S780) mAb (clone 
J146-35), mouse anti-Rb (ppRb S807/S811) 
mRb (clone J112-906) were purchased from 
BD Biosciences; rabbit anti-cyclin D3 mAb 
(clone EP463E), mouse anti-influenza A 
nucleoprotein mAb (clone AA5H), mouse 
anti-lamin B1 mAb (clone ZL-5), mouse 
anti-GAPDH mAb (clone 6C5) were 
purchased from Abcam; Texas 
Red-conjugated goat anti-rabbit IgG (H+L) 
(pAb), FITC-conjugated goat anti-mouse 
IgG (H+L) (pAb) were purchased from Life 
Technologies.  
 
GST pull-down 
A DNA fragment encoding the M2 gene 
of influenza virus A/WSN/33 strain was 
cloned into the pGEX4T-1 vector and 
expressed in Escherichia coli strain BL21. 
The resulting GST fusion protein was 
purified with glutathione-Sepharose beads 
(GE Healthcare) and added to A549 cell 
lysates. The empty vector expressing GST 
alone was used as negative control. After 
overnight incubation, beads were collected 
by centrifugation and washed five times to 
remove nonspecific binding. Bound proteins 
were resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and immunoblotting with 
indicated antibodies. 
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Co-immunoprecipitation 
HEK 293T cells were transfected with 
pCMV6-Flag-c-Myc-CCND3 plasmid in a 
10 cm dish. At 48 h post transfection, cells 
were infected with influenza A/WSN/33 
strain at a multiplicity of infection (MOI) of 
2 for 6 h before being lysed in buffer 
containing 50 mM Tris (pH7.4), 150 mM 
sodium chloride, 1% Triton X-100, 0.5% 
sodium deoxycholate, 1 mM EDTA, and 
protease inhibitors (Roche). Cell extracts 
were cleared by centrifugation and 
supernatant was incubated with anti-flag or 
isotype control antibody overnight at 4ºC. 
Protein G Sepharose beads (GE Healthcare) 
were then used to recover the immune 
complexes from whole cell lysates. 
Immunoprecipitated samples were washed 
five times with lysis buffer before being 
resolved by SDS-PAGE and detection by 
Western blotting. Interaction specificity 
study was performed in HEK 293T cells 
trasfected with plasmid encoding either one 
of c-Myc-tagged cyclin D1, D2, D3, or E1 
and targeted to similar treatment as 
described above for co-immunoprecipitation 
experiments. 
 
For competitive binding assays, HEK 
293T cells were co-transfected with 
pCAGGS-M1-HA and pCAGGS-M2-Flag 
plasmids, or with pCAGGS-M1-HA, 
pCAGGS-M2-Flag along with 
pCMV6-Flag-cMyc-CCND3 plasmids in 10 
cm dishes. Bulk cell lysates were prepared 
as described above at 48 h post transfection. 
Cleared cell extracts were incubated with 
anti-M2 (Santa Cruz) or isotype control 
antibody overnight at 4ºC, followed by 
recovery of the immune complexes from 
whole cell lysates using protein G 
Sepharose beads. Immunoprecipitated 
samples were washed six times with lysis 
buffer before being resolved by SDS-PAGE 
and detection by Western blotting. 
 
Synchronization of cells 
Lovastatin was used to synchronize cells 
in G1 phase. Briefly, culture medium was 
removed 24 h after the initial plating of 
A549 cells and replaced with fresh complete 
medium containing 40 µM lovastatin 
(Sigma-Aldrich). Cells were incubated in 
lovastatin for 22 h to achieve cell cycle 
G0/G1 phase synchronization prior to other 
experimental procedure. At time 0 hour, 
cells were allowed to re-enter cell cycle 
progression by replacing the medium with 
fresh complete medium supplemented with 
4 mM mevalonolactone (Sigma-Aldrich). 
The synchronization of cells at the G2/M 
transition by RO-3306 was as follows: at 24 
h following plating A549 cells, medium was 
replaced with fresh complete medium 
containing 4 µM RO-3306 (Calbiochem) 
and incubated for 18 h. Cells were then 
washed for three times with PBS and 
cultured in fresh complete medium to 
promote cell cycle progression.  
 
Cell cycle analysis 
Cell cycle profiles were analyzed by 
bromodeoxyuridine (BrdU) incorporation 
and DNA content staining. Briefly, 
pre-synchronized A549 cells were infected 
at an MOI of 2 with influenza A/WSN/33 
strain or mock infected. Immediately prior 
to collection, cells were incubated in 10 µM 
BrdU (Invitrogen) for one hour and fixed 
overnight in 70% ethanol at -20ºC. 
BrdU-pulsed cells were rescued from 
ethanol and denatured by 2 M hydrochloric 
acid with 0.5% Triton X-100 for 30 min at 
room temperature, followed by 
neutralization with 100 mM borate buffer 
(pH 8.5). BrdU labeling was revealed with 
Alexa Fluor 647 conjugated BrdU mouse 
Restriction of influenza infection by cyclin D3 
15 
	
mAb (clone MoBU-1; Invitrogen). Total 
DNA content was measured by 
7-amino-actinomycin D (7-AAD; BD 
PharMingen) staining. Cells were then 
immediately analyzed on a BD LSR II flow 
cytometer (BD Immunocytometry Systems). 
Approximately 30,000 cells were acquired 
for each sample and data were analyzed 
using FlowJo software (Treestar). 
 
Protein analysis and proteasome inhibition 
assay 
A549 cells were infected with A/WSN/33 
virus at an MOI of 2 or mock infected. At 
various time points after infection, cells 
were washed twice with ice-cold PBS and 
lysed in buffer containing 50 mM Tris 
(pH7.4), 150 mM sodium chloride, 1% 
Triton X-100, 0.5% sodium deoxycholate, 1 
mM EDTA, and protease inhibitors. After 
end-to-end rotation at 4ºC for 1 h to 
facilitate lysis, cell lysates were cleared by 
centrifugation at 20817 g/min for 30 min at 
4ºC. Whole cell lysates were further boiled 
at 95ºC for 10 min in 1X sample loading 
dye and 50mM DTT before being subjected 
to SDS-PAGE.  
To block ubiquitin mediated protein 
degradation, A/WSN/33 virus-infected 
(MOI of 2) or mock-infected A549 cells 
were incubated in fresh medium containing 
either 40 µM MG-101 (Sigma-Aldrich) or 5 
µM MG-132 (Sigma-Aldrich) at the start of 
infection. DMSO (Sigma-Aldrich) 
containing medium was used as vehicle 
control in this experiment. Whole cell 
lysates were collected 9 h after infection as 
described above. 
 
Subcellular fractionation 
For cell fractionation, A549 cells were 
infected at an MOI of 2 with influenza 
A/WSN/33 virus. At 8 h post-infection (p.i.), 
cells were washed twice with ice-cold PBS 
and lysed on dish with ice-cold buffer 
containing 25 mM Tris (pH7.4), 5 mM 
magnesium chloride, 150 mM sodium 
chloride, and 0.1% Triton X-100. 
Permeabilized cells were collected with a 
rubber policeman, and transferred into 
Eppendorf tubes. After a very brief 
incubation, supernatant (cytoplasm-enriched) 
and pellet (nuclear-enriched) fractions were 
separated upon centrifugation at 20817 
g/min for 30 sec at 4ºC. The nuclear fraction 
was then solubilized in buffer containing 25 
mM Tris (pH 7.4), 5 mM magnesium 
chloride, 150 mM sodium chloride, and 1% 
SDS. DNA shredder was used to process the 
nuclear fractions to shear the genomic DNA 
for easier SDS-PAGE gel loading of the 
samples. Sample loading dye and DTT at 
final concentration 1X and 50mM 
respectively was added into the lysate 
before boiling at 95ºC for 10 min. 
 
Colocalization assays 
  To capture subcellular colocalization 
between influenza M2 and cyclin D3, A549 
cells were transfected with a wild-type 
cyclin D3 plasmid 
(pCMV6-CCND3-cherry). 24 hours post 
transfection, cells were either mock or 
virus-infected with A/WSN/33 at a MOI 2. 
Cells were maintained in medium 
supplemented with 5µM MG132 for the 
duration of infection. 15 hours 
post-infection cells were collected for 
immunofluorescence assay. 
  To determine effect of cyclin D3 on 
co-localization between influenza M1 and 
M2, A549 cells were transfected with either 
an empty vector or cyclin D3 
(pCMV6-Flag-CCND3). 24 hours post 
transfection, cells were infected with 
influenza A/WSN/33 at a MOI 2. 10 hours 
post-infection, cells were collected for 
staining and confocal imaging of influenza 
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M1 and M2. 
 
Immunofluorescence assay 
A549 cells were plated onto glass 
coverslips one day prior to transfection or 
infection. Cells were washed with PBS and 
fixed in 4% paraformaldehyde (PFA) for 15 
min at the end of the experiments. 
Coverslips were incubated in 50 mM 
ammonium chloride for 10 min to quench 
the auto fluorescence of PFA before being 
permeabilized in PBS containing 0.1% 
Triton X-100 for 10 min. Cyclin D3 was 
stained with rabbit anti-cyclin D3 mAb 
(EP463E), followed by incubation with 
FITC-conjugated goat anti-rabbit IgG. The 
viral M2 protein was visualized by labeling 
with mouse anti-M2 mAb (14C2), followed 
by staining with Texas Red-conjugated goat 
anti-mouse IgG. The viral M1 protein was 
visualized by labeling with rabbit anti-M1 
pAb, followed by FITC-conjugated goat 
anti-rabbit IgG. After washing with PBS, 
coverslips were incubated with DAPI for 
nucleus staining and mounted in mowiol on 
glass slides. Images were acquired with a 
Zeiss LSM 700 confocal fluorescence 
microscope at the Faculty Imaging Core 
Facility of the University of Hong Kong. 
 
RNA interference and virus infection 
All gene-specific siRNAs were purchased 
from Dharmacon (Dharmacon Research). 
Individual siRNA against the 
5’-AAGGAUCUUUGUGGCCAAGGA-3’ 
sequence (62) or 
5’-UGCGGAAGAUGCUGGCUUA-3’ 
(D-003212-08) sequence of human cyclin 
D3 transcript and the non-targeting siRNA 
(D-001210) were used. SiRNAs for human 
cyclin E1 transcript (M-003213), human 
Rb1 transcript (M-003296) were provided 
as an siGENOME SMARTpool containing a 
mixture of four siRNAs targeting different 
sites of a single gene. A549 cells were 
transfected with siRNAs (final 
concentration of 100 mM for each gene) by 
using DharmaFECT 1 Transfection Reagent 
according to the manufacturer's protocol. 
Cells were sub-cultured 48 h 
post-transfection to avoid potential cell 
cycle arrest induced by over confluence.  
To study the effect of gene knockdown 
on influenza progeny virus production, 
siRNA-treated A549 cells or HBECs were 
infected with influenza viruses 24 h after 
seeding at an MOI of 0.01 in DMEM 
containing 0.3% BSA (Sigma-Aldrich), in 
the presence of 0.1 µg/ml TPCK-treated 
trypsin (Thermo Scientific). Supernatants 
were collected at 24 and 48 h p.i. and the 
progeny virus titers were obtained by plaque 
assay as described above. Separate wells 
without infection were used to determine the 
knockdown efficiency by Western blotting. 
The effect of siRNA treatment on 
influenza viral protein expression was 
investigated in cells prepared as described 
above. Cells were infected with A/WSN/33 
virus at an MOI of 2 and supplied with fresh 
cell culture medium containing 10% FBS 
and 100U/ml penicillin and 100µg/ml 
streptomycin after removing the virus 
inoculums. Whole cell lysates were 
prepared from individual wells at 3, 6, 9, 
and 12 h p.i. for Western blotting analysis. 
Cyclin D3-specific siRNA-treated and 
control A549 cells were infected at an MOI 
of 1 with A/WSN/33 virus to study the 
effect of cyclin D3 reduction on M2 plasma 
membrane expression. In order to 
synchronize viral entry, cells were incubated 
with virus at 4ºC for one hour, and replaced 
with pre-warmed fresh cell culture medium. 
Virus-infected cells were collected and 
fixed at 6 and 8 h p.i. for surface M2 
expression detection using anti-M2 mAb 
(Thermo Scientific) followed by 
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FITC-conjugated secondary antibody 
without permeabilization. Cells were then 
immediately analyzed on a BD LSR II flow 
cytometer (BD Immunocytometry Systems). 
Approximately 30,000 cells were acquired 
for each sample and data were analyzed 
using FlowJo software (Treestar). 
 
Absolute quantitative RT-PCR 
Gene expression patterns were 
determined by two step RT-PCR reactions. 
Briefly, total RNA was isolated from around 
1X105 HBEC and pneumocytes using 
RNeasy plus kit in combination with 
QIAshredder (Qiagen). Complementary 
DNA (cDNA) was then generated from the 
total RNA using SuperScript III First-Strand 
Synthesis System (Invitrogen) according to 
the manufacture’s recommendation. The 
cDNA product was used undiluted for 
HBEC or twenty-fold diluted for 
pneumocytes. Serial dilutions of plasmids of 
cyclin D1, D2, D3, and E1 with known gene 
copy numbers were used to generate 
standard curves for absolute quantification 
of the desired gene expression. The 
real-time PCR reactions were performed in 
25 µl reactions containing fluorigenic 
Taqman probe at a final concentration of 
400 nM together with 800 nM of each 
primer, and 12.5 µl 2X Probe Master 
(Roche). The assays were performed on the 
LightCycler 480 II (Roche) with thermal 
cycling conditions of 10 min at 95 ºC 
followed by 40 cycles of 95 ºC for 10 s, 60 
ºC for 1 min, and 72 ºC for 1 s. Each sample 
was quantified in triplicate for each 
experiment. Primers and probes were: 
5′-CTGTCCTACTACCGCCTCACA-3′ 
(forward), 
5′-GCCTTGGGGTCCATGTTCT-3′ 
(reverse), and 
5′-(FAM)CCAGAGTGATCAAGTGTGAC
CCAGACTGCC(TAMRA)-3′ (Taqman 
probe) for cyclin D1 (85); 
5′-GGGAACTGGTGGTGCTGG-3′ 
(forward), 
5′-TGGGTACATGGCAAACTTAAAGTC-
3′ (reverse), and 5′-(FAM) 
AAGCTGTCTCTGATCCGCAAGCATGC
(TAMRA)-3′ (Taqman probe) for cyclin D2 
(85); 
5′-TCCGGGGATGAGCTCACAGA-3′ 
(forward), 
5′-GGCTCTCCCTGAGTGCAGCTT-3′ 
(reverse), and 
5′-(FAM)TGGCAGGGATCACTGGCACT
GAAGTGGACT(TAMRA)-3′ (Taqman 
probe) for cyclin D3 (85); 
5’-GAAGATGATGACCGGGTTTAC-3’ 
(forward), 
5’-GAGCCTCTGGATGGTGCAA-3’ 
(reverse), and 
5’-(FAM)CAAACTCAACGTGCAAGCCT
CGGAT(TAMRA)-3’ (Taqman probe) for 
cyclin E1 (86). 
 
Statistical analysis  
Results are shown as mean ± standard 
deviation (SD) of the indicated number of 
experiments. Statistical difference between 
groups was determined by the unpaired 
Student’s t-test or two-way ANOVA, with a 
0.05 significance level.
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Table 1 Yeast two-hybrid screen identifies/predicts cyclin D3–M2-CT interaction 
Characteristic Value or description 
Bait M2 cytoplasmic tail (aa 44-97) 
Library Random-primed human placenta cDNA 
No. of interactions tested 63.89 million 
Prey cyclin D3 
No. of positive clones 42 
Confidence score* A 
Minimal interacting domain aa 138-251 
*Predicted biological score (from A to E – highest to lowest), a statistical confidence score 
assigned to each interaction by Hybrigenics. 
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FIGURE LEGENDS 
Figure 1 Identification of cyclin D3 as a specific cellular interactor of M2 influenza protein. 
(A) Schematic representation of structural motifs in the M2 protein with the enlarged 
sequence of the cytoplasmic tail (CT) used as the bait for the yeast two-hybrid screen. ED, 
ectodomain; TM, transmembrane domain. (B) Schematic representation of cyclin D3. The 
retinoblastoma (Rb)-binding LXCXE motif, the proline (P), glutamic acid (E), serine (S), and 
threonine (T)-rich PEST domain which has been postulated to be involved in the rapid 
degradation of unstable proteins, and the M2-minimal interacting domain are shown. 
Numbers indicate amino acid positions. (C) GST pull-down assay using whole cell lysates 
from A549 cells. Samples were incubated with either naked beads, GST control (GST) or 
GST fused to the cytoplasmic tail of A/WSN/33 virus M2 protein (GST–M2-CT), and 
analyzed by immunoblotting with anti-cyclin D3 antibodies after pull-down. Results are 
representative of three and two independent experiments for cyclin D3 and cyclin D1 
pull-down, respectively. Dotted lines indicate sliced lanes from the same gel. GST protein 
input was revealed by Coomassie Blue staining. (D) Co-immunoprecipitation of M2 with 
cyclin D3. HEK 293T cells infected with A/WSN/33 virus at an MOI of 2 were lysed at 6 h 
after infection and subjected to immunoprecipitation (IP) with anti-flag or isotype control 
antibodies. Cell lysates or pellets following IP were analyzed by immunoblotting (IB) using 
indicated antibodies. Transfection and infection conditions are shown on top of the blots. 
Results are representative of three independent experiments. (E) HEK 293T cells were 
transfected with plasmids encoding myc-tagged cyclins 48 h prior to infection with 
A/WSN/33 virus at an MOI of 2. Cells were lysed at 6 h after infection and subjected to 
immunoprecipitation (IP) with anti-myc or isotype control antibodies. Cell lysates or pellets 
following IP were analyzed by immunoblotting (IB) using indicated antibodies. Transfection 
and infection conditions are shown on top of the blots. M2 was found to interact with all 
cyclins tested, albeit, to different intensities. Results are representative of three independent 
experiments. Quantitation of M2 pull-down levels was performed by densitometric analysis 
of immunoblots. M2 level was normalized to the respective immunoprecipitated myc-tagged 
protein level in each condition. The degree of association of M2 to cyclin D1 was around 50% 
to that of cyclin D3 when same amount of cyclins were immunoprecipitated. Weak binding of 
M2 to cyclin D2 and cyclin E1, which plays a role in the cell cycle clock one step later than 
D-type cyclins and is required for cell cycle G1/S transition in association with 
cyclin-dependent kinase 2 (CDK2), was also observed in our experiments. Bar graph 
represents mean ± SD of three independent experiments. **P<0.005, ***P<0.0001 by the 
one-way ANOVA. 
 
 
Figure 2 Influenza A virus infection drives cyclin D3 re-distribution from nucleus to 
cytoplasm. (A) Cyclin D3 subcellular distribution is altered upon M2 expression. A549 cells 
were infected with A/WSN/33 virus at an MOI of 0.5 or transfected with a plasmid 
expressing M2 protein. At 24 h after infection or transfection cells were fixed for 
immunofluoresence staining. The subcellular localization of cyclin D3 (red) and M2 (green) 
was visualized through immunostaining with specific antibodies and analyzed by confocal 
microscopy. Yellow arrow heads point to nuclei of uninfected or non-transfected cells. White 
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arrows indicate virus infected or M2-expressing cells. Bar = 20 µm. (B) Cyclin D3 
translocates from nucleus to cytoplasm after viral infection. (Left panel) Cytoplasmic (C) and 
nuclear (N) fractions of virus-infected (MOI of 2) or uninfected cells were prepared from 
A549 cells 8 h after infection. Lysates were resolved by SDS-PAGE and immunoblotted with 
anti-cyclin D3. Levels of lamin B1 and GAPDH were used as controls to verify clean 
separation of nuclear and cytoplasmic fractions, respectively. Results are representative of 
three independent experiments. (C) Quantitation of cyclin D3 levels was performed by 
densitometric analysis of immunoblots. Data are presented as percentage of cyclin D3 
remaining in the nucleus as a fraction of total. Both mock- and virus-infection groups were 
normalized to total cyclin D3 levels in uninfected cells. Bar graph represents mean ± SD of 
three independent experiments. **P<0.005 by the unpaired Student’s t-test. (D) 
Colocalization of cyclin D3 and M2 in virus-infected cells. A549 cells expressing cyclin D3 
were infected with A/WSN/33 virus at an MOI of 2 in the presence of MG-132 to block 
protein degradation through proteasome and fixed at 15 h post infection. The subcellular 
localization of cyclin D3 (red) and M2 (green) was visualized through immunostaining with 
specific antibodies and analyzed by confocal microscopy. Bar = 20 µm. 
 
Figure 3 Influenza A virus (IAV) infection down regulates protein levels of cyclin D3 
through proteasome-mediated degradation. (A) IAV infection reduces protein level of cyclin 
D3 but not cyclin E. A549 cells were infected with A/WSN/33 virus at an MOI of 2. (Upper 
panel) Cells were lysed at specified time points, subjected to SDS-PAGE and visualized by 
Western blotting. Results are representative of three independent experiments. (Lower panel) 
Densitometric quantitation of cyclin D3 and cyclin E normalized to GAPDH. Line graphs 
represent mean ± SD from three independent experiments. *P<0.05, **P<0.01, ***P<0.001 
vs mock at each time point by the two-way ANOVA. (B) Cyclin D3 is targeted for proteolysis 
after viral infection. (Upper panel) A549 cells, either mock- or virus-infected, were treated 
with proteasome inhibitors MG-101 or MG-132 at the initiation of viral infection. Whole cell 
lysates were extracted at 9 h after infection for detection of cyclin D3 protein levels. (Lower 
panel) Densitometric analysis of immunoblots for cyclin D3 levels (normalized to GAPDH). 
Results are representative of three independent experiments. Bar graph presents mean ± SD 
from three independent experiments. *P<0.05 by the unpaired Student’s t-test. 
 
Figure 4 Influenza A virus (IAV) specifically targets cyclin D3 for proteasomal degradation. 
(A) IAV infection reduces protein level of cyclin D1, CDK4, and CDK6. A549 cells were 
infected with A/WSN/33 virus at an MOI of 2. Cells were lysed at specified time points, 
subjected to SDS-PAGE and visualized by Western blotting. Results are representative of 
three independent experiments. Line graphs represent mean ± SD of bands intensity obtained 
through densitometic quantitation from three independent experiments. **P<0.01, 
***P<0.001 vs mock at each time point by the two-way ANOVA. (B) Cyclin D3 is 
specifically targeted for proteolysis after viral infection. Virus-infected (MOI of 2) A549 cells 
were treated with proteasome inhibitors MG-101 or MG-132 at the initiation of viral infection. 
Whole cell lysates were extracted at 24 h p.i. for detection of the protein levels of cell cycle 
regulators. Results are representative of three independent experiments. Bar graph presents 
mean ± SD of band intensity obtained through densitometric analysis from three independent 
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experiments (normalized to GAPDH). *P<0.05, **P<0.005, ***P<0.001 by the unpaired 
Student’s t-test. 
 
Figure 5 Influenza A virus infection (IAV) leads to cell cycle arrest in G0/G1. (A) IAV 
infection altered the cell cycle progression of A549 cells pre-synchronized in G1 phase. A549 
cells were treated with lovastatin 22 h prior to infection with A/WSN/33 virus to synchronize 
them in G0/G1 phase. Cells were released from drug treatment at the start of infection 
(MOI=2), which lasted for the indicated time points, and incubated with 10 µM BrdU for cell 
cycle analysis 1 h before harvesting. (B) Cell cycle pattern of mock- and virus-infected cell 
populations at 24 h after infection that were pre-synchronized in G0/G1 phase with lovastatin. 
Results are representative of three independent experiments. (C) Percentage of cells in G0/G1 
phase after lovastatin treatment in mock- or virus-infected cells. Line graph illustrates mean ± 
SD of three independent experiments. ***P<0.001 vs mock at each time point by the 
two-way ANOVA. (D) IAV infection arrested cells in G0/G1 phase in A549 population 
pre-synchronized in G2/M phase. Cyclin dependent kinase 1 (CDK1) inhibitor RO-3306 was 
used to accumulate A549 cells in G2/M for 18 h. Immediately after drug removal, cells were 
infected with A/WSN/33 virus (MOI=2) and treated as above for cell cycle analysis following 
BrdU incorporation. (E) Cell cycle pattern of mock- and virus-infected cell populations that 
were pre-synchronized in G2/M phase with RO-3306. Results are representative of three 
independent experiments. (F) Percentage of cells in G0/G1 phase after RO-3306 treatment in 
mock- or virus infected cells. Line graph illustrates mean ± SD of three independent 
experiments. ***P<0.001 vs mock at each time point by the two-way ANOVA. Flow 
cytometry data were obtained with a BD LSRII flow cytometer. Scattergrams are 
representative of three independent experiments. In panel A and D, scattergrams show DNA 
content staining versus BrdU incorporation of each individual cell for cell cycle status 
determination. Boxed and circled areas define cell populations in each phase of the cell cycle 
indicated on graph. 
 
Figure 6 IAV infection inhibits hyper-phosphorylation of Rb and down-regulates 
cyclin-dependent kinase (CDK) inhibitor p21WAF1/CIP1. (A) A549 cells were infected with 
A/WSN/33 virus at an MOI of 2. At indicated time points, whole cell lysates were prepared 
from both infected and uninfected cells to determine the phosphorylation status of Rb and 
levels of CDK inhibitor p21WAF1/CIP1. Results are representative of three independent 
experiments. (Right panel) Densitometric analyses of Rb and p21WAF1/CIP1 levels were 
performed on immunoblots (normalized to GAPDH). Line graphs represent mean ± SD of 
three independent experiments. *P<0.05, **P<0.001 vs mock at each time point by the 
two-way ANOVA. (B) P21WAF1/CIP1 is targeted for proteolysis after viral infection. (Left panel) 
A549 cells, either mock- or virus-infected, were treated with proteasome inhibitors MG-101 
or MG-132 at the initiation of viral infection. Whole cell lysates were extracted at 9 h after 
infection for detection of p21WAF1/CIP1 protein levels. (Right panel) Densitometric analysis of 
immunoblots for p21WAF1/CIP1 levels in cells treated with different inhibitors (normalized to 
GAPDH). Results are representative of three independent experiments. Bar graph presents 
mean ± SD from three independent experiments. **P<0.005, ***P<0.0005 by the unpaired 
Student’s t-test. 
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Figure 7 Cyclin D3 negatively modulates influenza virus infection. (A) Analysis of 
siRNA-mediated gene knockdown efficiency. Whole cell lysates were prepared from A549 
cells 72 h after designated siRNA treatment. Western blotting was used to determine the 
expression levels of cyclin D3 and cyclin D1. Results are representative of three independent 
experiments. (B) Ccnd3 knockdown in A549 cells facilitate both low pathogenic and highly 
pathogenic IAV infection. Nontargeting (NT) or cyclin D3 (CCND3 #1 & CCND3 #2) 
siRNA treated cells were infected with viruses at an MOI of 0.01 for multi-cycle infection. 
Progeny virus titers in cell culture supernatants were determined through plaque assay. Bar 
graphs depict mean ± SD of three independent experiments. *P<0.05, **P<0.01, 
***P<0.0001 vs control (NT) siRNA at each time point by the unpaired Student’s t-test. (C) 
Analysis of siRNA-mediated gene knockdown efficiency. Lysates were prepared from A549 
cells treated with indicated siRNAs 72 h post transfection. The expression levels of 
retinoblastoma (Rb), cyclin E, cyclin D3, cyclin D1, and GAPDH proteins were determined 
by Western blotting. Results are representative of three independent experiments. (D) Cell 
cycle pattern of siRNA treated cells. A549 cells were fixed in 70% ethanol 72 h post siRNA 
treatment. The cell cycle pattern of each group was quantitated through BrdU incorporation 
and 7-AAD DNA content staining. Data were obtained with a BD LSRII flow cytometer and 
presented as the percentage of total cells in each phase. Bar graph represents mean ± SD of 
three independent experiments. **P<0.001, ***P<0.0001 vs NT siRNA by the unpaired 
Student’s t-test. (E) Cyclin D3 depletion in A549 cells increases progeny virus titer in 
supernatant. A549 cells treated with the indicated siRNAs were infected with influenza 
A/WSN/33 (H1N1) virus, A/HK/1/68 (H3N2), or A/HK/54/98 (H1N1) virus at an MOI of 
0.01. Cell culture supernatants were collected at 24 and 48 h after infection and virus titers 
were determined by plaque assay on MDCK cells. Bar graphs represent mean ± SD of three 
independent experiments. *P<0.05, **P<0.01, ***P<0.0005 vs NT siRNA by the unpaired 
Student’s t-test. 
 
Figure 8 Cyclin D3 is expressed along human airway. (A) Total RNA extracted from human 
bronchial epithelial cells (HBEC) and pneumocytes was reverse transcribed into cDNA for 
Taqman probe-based q-PCR gene expression analysis. Shown is a graphical representation of 
the mean absolute copy number of cyclin D1, D2, D3, and E1 in HBEC and pneumocyte. (B) 
Whole cell lysates of A549, HBEC, and pneumocyte were extracted to determine the protein 
levels of designated cyclins through Western blotting (Upper panel). Densitometric analysis 
of immunoblots for cyclin D1, D2, and D3 in different cell types were shown at lower panel 
(normalized to GAPDH). (C) Analysis of siRNA-mediated gene knockdown efficiency in 
HBEC. Whole cell lysates were prepared from HBECs cells 72 h after designated siRNA 
treatment. Western blotting was used to determine the expression levels of cyclin D3. (D) 
Ccnd3 knockdown in HBEC facilitates IAV progeny virus production. Nontargeting (NT) or 
cyclin D3 (CCND3 #2) siRNA treated cells were infected with viruses at an MOI of 0.01 for 
multi-cycle infection. Progeny virus titers in cell culture supernatants were determined 
through plaque assay. Bar graphs depict mean ± SD of three independent experiments. 
*P<0.05, **P<0.01, ***P<0.0001 vs control (NT) siRNA at each time point by the unpaired 
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Student’s t-test. 
 
 
Figure 9 Cyclin D3 deficiency does not affect viral protein synthesis. (Upper panel) A549 
cells with knockdown of indicated genes were infected with A/WSN/33 virus at an MOI of 2 
to determine their effect on viral protein synthesis. Whole cell lysates were collected at 3, 6, 9, 
and 12 h after infection to monitor protein levels. Lysates were resolved by SDS-PAGE and 
levels of viral nucleoprotein, M1, and M2 were determined through Western blotting. Results 
are representative of three independent experiments. (Lower panel) Densitometric analyses of 
immunoblots for each protein at 12h post-infection (normalized to GAPDH). Results are 
shown as mean ± SD of three independent experiments.  
 
Figure 10 Cyclin D3 competes with M1 for M2 binding. (A) Cyclin D3 impairs interaction 
between viral M2 and M1 proteins. (Left panel) HEK 293T cells were co-transfected with 
M1-HA and M2-Flag (Lane 1), or with M1-HA, M2-Flag along with cyclin D3-Flag (Lanes 2 
& 3), as indicated on top of each blot. At 48 h post transfection, cell lysates were collected 
and subjected to immunoprecipitation using anti-M2 (Lane 1 & 2) or isotype control (Lane 3) 
antibodies. Precipitates were analyzed through Western blotting to detect M1, M2 and cyclin 
D3 proteins. (Right panel) Densitometric analyses of immunoblots to quantitate the amount of 
viral M1 protein co-immunoprecipitating with M2 with or without the expression of cyclin 
D3 (normalized to immunoprecipitated M2 amount). Results are shown as mean ± SD of 
three independent experiments. **P<0.005 by the unpaired Student’s t-test. (B) Cyclin D3 
hinders M2 cell surface expression. (Left panel) Control and cyclin D3-deficient cells were 
infected with A/WSN/33 and plasma membrane expression of viral M2 protein was detected 
by flow cytometry at 6 and 8 h after infection. Histograms are representative of three 
independent experiments. Gating indicates cell populations that are positive or negative for 
plasma membrane expression of M2 protein. (Right panel) Statistical analysis of percentage 
of cells that were positive for surface expression of M2. Results are shown as mean ± SD of 
three independent experiments. **P<0.005 ***P<0.0001 by the unpaired Student’s t-test. (C) 
Overexpression of cyclin D3 sequestered viral M1 and M2 protein to secretory network. 
A549 cells were overexpressed with cyclin D3 protein 24 h prior to infection with A/WSN/33 
virus at an MOI of 2. Cells were fixed at 10 h p.i. and immunostained with specific antibodies 
to reveal the subcellular localization of M1 (red) and M2 (green). Bar = 20 µm. 
 
 
 
Figure 11 Working model of cyclin D3 function in the context of influenza virus budding. In 
normal cells cyclin D3 displays nuclear-localization, which is essential for cell-cycle 
regulation. During influenza A virus infection, cyclin D3 interacts with viral M2 protein. The 
cyclin D3-M2 interaction impairs binding of M2 to M1, which is required for virus assembly 
and budding at the plasma membrane. In the absence of cyclin D3, more infectious progeny 
virus particles are released into the supernatant of virus-infected cells. Influenza virus, 
however, antagonizes cyclin D3 inhibition by: i) redistributing cyclin D3 between nucleus and 
cytoplasm, which contributes to cell cycle G0/G1 arrest, thus facilitating virus replication; ii) 
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targeting cyclin D3 is to the proteasomal degradation pathway in the cytoplasm to remove its 
interference with M1-M2 binding. 
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